Wang Guo-Guang, Lu Xiao-Hua, Ding Min, Tang Wen-Tian, Li Wei, Zhao Xue, Zhang Cui
Department of Pathophysiology, Wannan Medical College, Wuhu 241002, China.
Sheng Li Xue Bao. 2011 Apr 25;63(2):177-83.
The aim of the study is to explore the effects of luteolin preconditioning on hepatic ischemia/reperfusion injury in rats and its mechanism, and investigate the effects of the change of heme oxygenase-1 (HO-1) activity on hepatic ischemia/reperfusion injury. Sprague-Dawley rats were divided into 5 groups randomly: control, model, luteolin, luteolin + zinc protoporphyrin (ZnPP, an inhibitor of HO-1) and hemin groups (n = 8 for each group). The rats in control, model and hemin groups received a standard chow daily. The rats in luteolin and luteolin + ZnPP groups received a chow supplemented with luteolin (200 mg/kg) daily. After 4 weeks, ZnPP (25 μmol/kg) and hemin (20 μmol/kg) were injected hypodermically 6 h before ischemia/reperfusion in luteolin + ZnPP and hemin groups, respectively. Portal vein and hepatic artery supplying the middle and left hepatic lobe were clamped with an atraumatic vascular clip for induction of partial hepatic ischemia in all rats except control group. After the 60 min of hepatic ischemia, a 60-minute reperfusion period was initiated by removal of the arterial clip. The levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were detected in serum, and the activity of superoxide dismutase (SOD) and the content of malondialdehyde (MDA) in serum and liver were measured with assay kit. The expression of HO-1 protein and activity of HO-1 were examined in liver. The results showed that the luteolin and hemin pretreatment led to significant decreased levels of AST and ALT in serum, increased activity of SOD and decreased content of MDA in serum and liver compared with model group (P < 0.01). In addition, the expression of HO-1 protein and activity of HO-1 were elevated in luteolin and hemin groups (P < 0.01). ZnPP markedly increased the levels of AST and ALT in serum, and decreased the activities of SOD and HO-1, elevated MDA content in liver when compared with those in luteolin group (P < 0.01). Cytoplasmic vacuolation and swelling of hepatocytes were revealed in the model group after ischemia/reperfusion. Treatments with luteolin and hemin markedly relieved the liver structural changes. These results suggest that HO-1 protects rat liver from ischemia/reperfusion injury, and luteolin reduces the content of MDA and increases the activity of SOD and the expression of HO-1, which indicate that luteolin can elevate the antioxidation in rat liver, and thus protects rat liver from ischemia/reperfusion injury.
本研究旨在探讨木犀草素预处理对大鼠肝脏缺血/再灌注损伤的影响及其机制,并研究血红素加氧酶-1(HO-1)活性变化对肝脏缺血/再灌注损伤的影响。将Sprague-Dawley大鼠随机分为5组:对照组、模型组、木犀草素组、木犀草素+锌原卟啉(ZnPP,HO-1抑制剂)组和血红素组(每组n = 8)。对照组、模型组和血红素组大鼠每日给予标准饲料。木犀草素组和木犀草素+ZnPP组大鼠每日给予添加木犀草素(200 mg/kg)的饲料。4周后,木犀草素+ZnPP组和血红素组分别在缺血/再灌注前6 h皮下注射ZnPP(25 μmol/kg)和血红素(20 μmol/kg)。除对照组外,所有大鼠均用无损伤血管夹夹闭供应肝中叶和左肝叶的门静脉和肝动脉以诱导部分肝脏缺血。肝脏缺血60 min后,移除动脉夹开始60分钟的再灌注期。检测血清中天冬氨酸转氨酶(AST)和丙氨酸转氨酶(ALT)水平,并用试剂盒测定血清和肝脏中超氧化物歧化酶(SOD)活性和丙二醛(MDA)含量。检测肝脏中HO-1蛋白表达和HO-1活性。结果显示,与模型组相比,木犀草素和血红素预处理导致血清中AST和ALT水平显著降低,血清和肝脏中SOD活性增加,MDA含量降低(P < 0.01)。此外,木犀草素组和血红素组中HO-1蛋白表达和HO-1活性升高(P < 0.01)。与木犀草素组相比,ZnPP显著增加血清中AST和ALT水平,降低SOD和HO-1活性,升高肝脏中MDA含量(P < 0.01)。缺血/再灌注后模型组可见肝细胞胞质空泡化和肿胀。木犀草素和血红素处理显著减轻了肝脏结构变化。这些结果表明,HO-1可保护大鼠肝脏免受缺血/再灌注损伤,木犀草素降低MDA含量,增加SOD活性和HO-1表达,这表明木犀草素可提高大鼠肝脏的抗氧化能力,从而保护大鼠肝脏免受缺血/再灌注损伤。